Navigation Links
Verenium Reports Financial Results for the Third Quarter 2010
Date:11/9/2010

CAMBRIDGE, Mass., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today reported a summary of recent Company highlights and financial results for the third quarter of 2010.

"I am pleased with the significant progress made across the business over the last quarter; we continue to see solid progress growing and diversifying our product sales and improved performance at the gross margin level," said Carlos A. Riva, President and Chief Executive Officer of Verenium. "Further, we remain committed to using our financial resources to accelerate the development of our current products and our pipeline."

Company HighlightsDuring 2010 Verenium has made significant progress on both the operational and financial fronts.  Most recent accomplishments include:

Operational/Industry Performance:

Animal Health and Nutrition

  • Achieved a 34% increase in 2010 year-to-date profit share from Phyzyme sales over the same period in 2009 due to strong demand for Phyzyme phytase.

  • Grain Processing

  • Launched Deltazym® GA L-E5 for fuel ethanol production, which together with Fuelzyme, allows us to satisfy the complete enzyme requirements of corn ethanol producers; and
  • Grew 2010 year-to-date revenues from the Company's grain processing enzymes, including Fuelzyme, Deltazym, Veretase and Xylathin, by 37% over the same period in 2009; grain processing has grown to represent more than 25% of 2010 year-to-date product revenues.

  • Oilseed Processing

  • Received regulatory approval for sale of Purifine® PLC in China, completing the product's approval for sale in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United S
    '/>"/>

  • SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Verenium to Present at Jefferies 10th Global Clean Technology Conference
    2. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
    3. Verenium Announces Regulatory Approval for Purifine® PLC in China
    4. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
    5. Verenium Appoints Kevin Bracken Vice President of Manufacturing
    6. Verenium Announces Proposed Public Offering of Common Stock
    7. Verenium 1:12 Reverse Stock Split Takes Effect
    8. Verenium Announces Reverse Stock Split to Take Effect September 9
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Completes Amendment to 8% Senior Convertible Notes
    11. Verenium Announces Organizational Changes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
    (Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
    (Date:2/27/2015)... Md. (PRWEB) February 27, 2015 ... Chromatography system (Nexera UC) can sequentially analyze up ... separation combined with high-sensitivity detection of targets by ... is designed to fulfill the measurement requirements of ... in food products, drug delivery and search for ...
    (Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
    Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
    ... CAMBRIDGE, Mass., Oct. 31 Idenix,Pharmaceuticals, Inc., (Nasdaq: ... results for the third quarter of 2007 on Tuesday, ... In conjunction with the issuance of the press release, ... ET on Tuesday, November,6, 2007 to discuss the company,s ...
    ... tech development, opportunities for business growth, COLUMBUS, ... Ohio,colleges and universities increased academic research expenditures in ... than ever into high,technology R&D sectors throughout the ... high tech research, development and,commercialization, especially in the ...
    ... SAN FRANCISCO, Oct. 31 Medivation, Inc.,(Nasdaq: MDVN ... chief,executive officer, will present at the Acumen BioFin Rodman ... at 11:15 a.m. Eastern,Time at the New York Palace ... Medivation and its clinical,development programs for Dimebon(TM) for Alzheimer,s ...
    Cached Biology Technology:Ohio Academic Institutions Increase Research and Development Investments 2Ohio Academic Institutions Increase Research and Development Investments 3Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
    (Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
    (Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
    (Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
    Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
    ... Haven, Conn.Paleontologists have discovered a new species of dinosaur with ... skull, according to a paper published in the April issue ... species was a plant-eating dinosaur about as big as a ... said Nicholas Longrich of Yale University, lead author of the ...
    ... RIVERSIDE, Calif. Robert Luck , a professor of ... California Citrus Quality Council,s prestigious Albert G. Salter Memorial Award ... Luck is a leading expert in the research ... "This is a truly deserving award for Professor Luck ...
    ... The Marine Protected Areas Federal Advisory Committee will meet ... Charleston, S.C. The committee advises the Department of Commerce ... to the national system of MPAs. The ... includes integrating the national MPA system with the Coastal ...
    Cached Biology News:New bony-skulled dinosaur species discovered in Texas 2UC Riverside entomologist recognized for research in citrus entomology 2
    The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
    Request Info...
    ... The Cellject Uno Electroporator is ... for producing optimum efficiencies in bacterial ... simply selects one of two voltages ... or four mm cuvettes. On pressing ...
    Request Info...
    Biology Products: